Filter news by date News Tags - Any -News storyPress release Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year Year2024202320222021202020192018201720162015201420132012201120102009200820072006 Apply 8 . 29 . 2024 Press release Galderma successfully issued an inaugural CHF 500 million bond 8 . 13 . 2024 Press release Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis 8 . 5 . 2024 Press release Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology 7 . 30 . 2024 Press release Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe 7 . 25 . 2024 Press release Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024 7 . 25 . 2024 Press release Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance 7 . 9 . 2024 Press release Galderma introduces high potency Cetaphil serums designed for sensitive skin 7 . 1 . 2024 News story Shaping the future: Gerry Muhle on the technologies driving dermatology 6 . 19 . 2024 Press release Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence 6 . 3 . 2024 News story Acne Awareness Month 2024: understanding acne scarring 5 . 23 . 2024 Press release Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets 5 . 7 . 2024 Press release Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries 4 . 24 . 2024 Press release Galderma delivers a strong start to the year with record net sales of over 1 billion USD for the first quarter and 12.4% year-on-year growth Pagination Next page Next Page